Overview

HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
This trial was conducted previously by Cormorant